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Rhabdomyosarcomas (RMSs) are the most common soft tissue sarcomas of childhood and adolescence. To date, there are no
eﬀective treatments that target the genetic abnormalities in RMS, and current treatment options for high-risk groups are not
adequate. Over the past two decades, research into the molecular mechanisms of RMS has identiﬁed key genes and signaling
pathways involved in disease pathogenesis. In these studies, members of the receptor tyrosine kinase (RTK) family of cell surface
receptors have been characterized as druggable targets for RMS. Through small molecule inhibitors, ligand-neutralizing agents,
and monoclonal receptor-blocking antibodies, RTK activity can be manipulated to block oncogenic properties associated with
RMS. Herein, we review the members of the RTK family that are implicated in RMS tumorigenesis and discuss both the problems
and promise of targeting RTKs in RMS.
1.Introduction
The most common soft tissue sarcomas of childhood and
adolescence are rhabdomyosarcomas (RMSs). These malig-
nancies express skeletal muscle markers but are believed to
betheresultofdysregulated skeletalmusclediﬀerentiationof
mesenchymal precursors. Like other sarcomas, RMS tumors
are molecularly diverse; histological classiﬁcation separates
RMS into two major types, embryonal (eRMS) and alveolar
rhabdomyosarcoma (aRMS). As the name implies, eRMS
tumorsconsist ofcells morphologically similar to embryonic
muscle precursors. The histology of aRMS tumors is distinc-
tive, with clusters of primitive, round cells and open spaces
between cell sheets developing upon ﬁxation in formalin,
vaguely resembling lung alveoli [1]. The eRMS and aRMS
subtypes diﬀer not only in histological appearance but also
in prognosis. Patients with eRMS have a generally favor-
able prognosis, while patients with aRMS do signiﬁcantly
worse, with a ﬁve-year survival rate of less than 50% [2].
Furthermore, aRMS can be speciﬁed by the presence of a
chromosomal translocation resulting in a PAX3-FOXO1 (or
the less frequent PAX7-FOXO1, PAX3-NCOA1,o rPAX3-
NCOA2 [3]) gene product. When metastatic, PAX3-FOXO1-
positive aRMS patients survive in fewer than 10% of cases
[4]. Although staging of RMS still utilizes histology, recent
gene proﬁling studies have suggested that a more accurate
classiﬁcation of RMS might be as fusion gene positive or
negative [5, 6]. Thus, modiﬁed classiﬁcation of RMS may
lead to better risk stratiﬁcation at diagnosis and direct
appropriate therapy.
Treatment for RMS has depended on a multimodal
approach ofsurgery,chemotherapy,andradiation. Thisteam
strategy has resulted in an overall survival of RMS at about
70% [7]. But as described above, high-risk patients have
a poor prognosis, and treatment options are limited. It is
believed that without targeted therapies speciﬁc for genetic
abnormalities associated with RMS, the survival rate will not
improve.
Over the past two decades, research into the molecular
mechanisms of RMS has identiﬁed key genes and signaling
pathways involved in disease pathogenesis. Opportunely,
many groups have identiﬁed favorable molecular targets for2 Sarcoma
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Figure 1: Rationale for dual treatment targeting the IGF-1R
signaling pathway in RMS. Rapamycin inhibits mTOR signaling,
preventing inhibitory feedback on IRS-1 which allows proliferative
signals from IGF-1R to IRS-1, PI3K, and AKT. Dual treatment
using rapamycin in combination with IGF-1R inhibition, such as
monoclonalblocking antibodies, prevents signalingto these critical
progrowth signaling nodes.
inhibition, such as cell surface receptors. In this review, we
will describe the receptor tyrosine kinases (RTKs) associated
with RMSand subsequentlydiscuss thetherapeuticpotential
of these targets.
2.ReceptorTyrosine KinasesAssociated with
Rhabdomyosarcoma
2.1. IGF-1R. The IGF-1R is a 150-kDa transmembrane RTK
expressed on almost all mammalian cells. It is a classical
RTK, signaling through ligand occupancy, dimerization,
and transmembrane signaling to the cytoplasm through
the IRS-1 and IRS-2 adaptor proteins. Present during both
embryogenesis and postnatally, IGF-1R is critical for the
growth of a variety of mammalian tissue types [8]. In
myogenesis, IGF-1R is essential for myoblast proliferation,
and IGF ligands induce a strong proliferative response in
myogenic precursors. IGF-1R signaling is also necessary
for myogenic diﬀerentiation through upregulation of the
myogenic cascade [9]. There are two known IGF-1R ligands,
IGF-1 and IGF-2. While both of these ligands have a
ubiquitous tissue distribution, IGF-1 is considered to exert
its eﬀects postnatally, while IGF-2 is thought to be dominant
during embryogenesis [10]. Through numerous in vitro
and in vivo studies performed by many groups, it is well
established that IGF activation of IGF-1R is critical for both
proliferation and diﬀerentiation of muscle cells.
The original evidence for upregulation of IGF-1R sig-
naling in RMS came from early studies of IGF ligands
in pediatric tumors. As such, IGF-2 was found to be
upregulated in both primary RMS tumor samples and cell
lines [11, 12], mechanistically the result of loss of imprinting
of the maternal or duplication of the active IGF2 allele
[13, 14]. IGF-1R was later found to be upregulated in aRMS
by the PAX3-FOXO1 fusion gene [15]. In this way, increased
expression of both IGF-2 and IGF-1R leads to a strong
mitogenic feed-forward signaling loop within the tumor.
The role of the IGF-1R signaling pathway in RMS has
been examined through experimental loss of function using
multiple approaches. Antisense constructs, small molecule
inhibitors, and receptor blocking antibodies to IGF-1R have
all shown antiproliferative eﬀects in preclinical studies of
RMScelllinesandxenografts[12,16–25].Themechanism of
action appears to be through inhibition of cell proliferation
by arrest in the G1 stage of the cell cycle due to downreg-
ulation of CDK1 [19, 21]. Interestingly, cell lines that were
the most sensitive to IGF-1R blockade were those with the
highest levels of IGF-1R expression [16].
An understanding of the signaling pathways downstream
ofIGF-1Rhasbeenenhancedthroughstudiesusingthesmall
molecule inhibitor, rapamycin. Rapamycin inhibits mTOR,
a PIKK family member kinase that responds to changes in
nutrient availability and cellular stresses. RMS sensitivity to
rapamycin is mediated by IGF-1R signaling, demonstrating
that the mTOR pathway is downstream of IGF-1R [17, 26].
As shown in Figure 1, in the IGF-1R signaling pathway, IGF-
1R signals to IRS-1 and AKT, which then signals to mTOR.
Paradoxically, treatment of cancer cells with rapamycin
activates AKT, due to blockade of a feedback loop via
ribosomal S6 kinase (S6K)that normally inhibits IRS-1 [27].
This eﬀect can be reversed by inhibiting IGF-1R. Through
dual treatment of RMS tumors with rapamycin and IGF-
1R inhibitors, the proliferative IGF-1R signaling cascade can
be dramatically reduced. In this way, IGF-1R blockade has
become an attractive proposed treatment for RMS and other
IGF-driven cancers [16, 28, 29].
IGF-1R inhibitors are one of many classes of compounds
tested in the Pediatric Preclinical Testing Program (PPTP).
This NCI-funded program provides a preclinical screening
platform to test new agents that may have activity against
pediatric cancers. As shown in Table 1, the IGF-1R inhibitor
IMC-A12 showed eﬀectiveness in RMS xenografts, while
SCH 717454 had a partial eﬀect. These studies, in addition
to the preclinical data described above, provide a strong
rationale to pursue IGF-1R inhibitors in clinical trials for
pediatric RMS patients.
As shown in Table 2, phase I and phase II trials of RTK
small molecule inhibitors, monoclonal antibodies against
RTK ligands, and monoclonal antibodies against RTKs have
been under investigation since the year 2000. Notably,
inhibition of IGF-1R with monoclonal antibodies has been
the most recent focus of these trials and, if successful, will be
the ﬁrst FDA-approved RTK-targeted therapy for RMS.
2.2. MET. MET is a proto-oncogene RTK necessary for cell
proliferation, motility, and epithelial-mesenchymal transi-
tion. Similar to IGF-1R, MET is also 150kDa and shows
broad tissue expression in embryonic and postnatal tissues.
In contrast to IGF1-1R, MET has only one ligand, termed
hepatocyte growth factor (HGF). In the context of myogene-
sis, limb mesenchyme secretes HGF, which directs myogenic
precursors to the limb bud. In this way, MET signaling regu-
lates delamination and migration of muscle precursors from
the embryonic dermomyotome [30]. MET also promotes
cell proliferation in muscle precursors when activated with
HGF in vitro [31]. When these cells stop proliferating and
induce diﬀerentiation, HGF and MET expression decreases
[32]. Thus, MET promotes both myoblast proliferation and
migration processes in normal cells.Sarcoma 3
Table 1: Results of RTK inhibitors used in Pediatric Preclinical Testing Program.
Intended target Inhibitor Additional
targets
In vivo response,
RMS xenografts∗ Conclusions Ref.
EGFR, ErbB2 Lapatinib Erk1/2, Akt 1/5 Limited eﬀectiveness in all xenografts tested [30]
IGF-1R IMC-A12 N/A 6/6 Tumor growth inhibition in most solid tumor
xenografts, most eﬀective in RMS xenografts [25]
IGF-1R SCH 717454 N/A 2/4 Tumor growth inhibition in many solid tumor
xenografts [31]
PDGFR Sunitinib
c-KIT,
VEGFR2,
FLT3
5/6 Tumor growth delay, inhibition in most solid
tumor xenografts [32]
Raf1 Sorafenib
VEGFR,
PDGFR, RET,
FLT3, c-KIT
2/6 Tumor growth inhibition in various tumor
xenografts [33]
SRC Dasatinib
ABL, c-KIT,
EPHA2,
PDGFR
1/6 Limited eﬀectiveness in solid tumor xenografts [34]
VEGFR1-3 AZD2171 PDGFR,
c-KIT 5/5 Tumor growth inhibition in most solid tumor
xenografts [35]
∗Xenografts with “intermediate” or “high” response activity as deﬁned by Maris et al. [50].
HGF is also known as “scatter factor,” referring to its
ability to induce cell motility. Accordingly, MET has been
implicated in cytoskeletal reorganization and migration in
cancer cells. In RMS cells, HGF promotes chemotaxis and
invasion [33–35]. Because of these migratory eﬀects of
HGF/MET signaling, the role of this signaling pathway in
tumor cell metastasis has been examined. Cells derived from
bone marrow secrete HGF, and RMS cells have been shown
to home to bone marrow, due in part to MET expression
[33, 35, 36]. Furthermore, bone marrow aspirates from
RMS patients with metastatic disease have elevated MET
expression [37]. Therefore, a major role for MET is to confer
migratory and metastatic properties.
MET-null and Splotch (PAX3 mutant) mice both exhibit
loss of muscle precursor colonization in the limb bud
[30, 38], which revealed an association of PAX3 with MET
expression [39]. MET is a transcriptional target of PAX3
and PAX3-FOXO1, and RMS cell lines and tumors express
elevated levels of MET compared to normal muscle [34, 40,
41]. Targeted knockdown of MET in human RMS cell lines
decreases RMS cell proliferation in vitro and tumor burden
in mouse xenograft models [35, 42]. Therefore, in addition
to regulating migration and metastasis, MET also appears to
regulate proliferative properties in RMS.
Several genetically engineered mouse models of RMS
either exploit MET signaling or demonstrate deregulated
METexpression.Themost robustmurinemodelofRMSwas
generated through manipulation of the HGF/MET signaling
axis. While transgenic HGF mice were predisposed to a
low incidence of many types of cancers, including skeletal
muscle-derived tumors [43], transgenic HGF mice with
a targeted deletion of the INK4A/ARF locus had a near
complete penetrance of eRMS in young animals [44]. Mouse
models utilizing the PAX3-FOXO1 fusion gene have also
deﬁned roles for MET. Conditional replacement of PAX3
with PAX3-FOXO1 results in abnormal delamination of
myogenic progenitors from the somite that can be reversed
with expression of a kinase-inactive MET [45]. aRMS has
been modeled by conditional PAX3-FOXO1 at the PAX3
locusin eitheran INK4A/ARF orp53-null background.MET
upregulation was observed in all tumors derived, regardless
of the genetic background [46].
Although there is clear evidence for the involvement of
MET in RMS initiation, progression, and metastasis, to date
there have been no clinical trials evaluating MET inhibition
in the context of RMS. Since MET is implicated in many
adultmalignancies, and phase I clinicaltrials for monoclonal
antibodies and small molecule inhibitors with anti-MET
activity have recently begun, we should expect to see trials
recruiting pediatric RMS patients.
2.3. EGFR, ErbB2. The ErbB family of RTKs is comprised
of four members: EGFR (ErbB1, HER1), ErbB2 (HER2),
ErbB3 (HER3), and ErbB4 (HER4). Members of this family
are similar in size, at 190kDa, and each are necessary
for embryonic development. Each has been implicated in
cancerinitiationandprogressionbutindiﬀerenttissuetypes.
Notably,ErbB3 is a noncatalyticreceptor but exerts an onco-
genic function through heterodimerization with other ErbB
family members [47]. ErbB receptors regulate multiple levels
of cell physiology in diﬀerent tissues, including cytoskeletal
rearrangement, proliferation, and evasion of apoptosis. In
mouse myoblasts, EGFR is expressed and is active in both
undiﬀerentiated and diﬀerentiated cells. EGFR blockade in
murine myotubes induced cell death, suggesting that EGFR
regulates prosurvival signaling in myogenic cells [48]. EGFR
has been associated with many adult malignancies, including
breast, non-small cell lung cancer, glioblastoma, head and
neck, gastric, genitourinary, and colorectal carcinomas [49].
Prognosis in these cancers can often be estimated by the
presence or absence of EGFR mutations, deletions, or
overexpression.4 Sarcoma
Table 2: Clinical trials evaluating drugs that target RTKs or their ligands, with strata that include rhabdomyosarcoma.
RMS tumor eligibility
Patient
age
(years)
Drug
Intended
RMS
Target
Additional Targets Phase Start date Sponsor/ collaborator
Small molecule inhibitors
Relapsed/refractory ≥15 Imatinib PDGFR ABL, c-Kit I/II Aug 2000 EORTC
Resistant
≥15 but
≤70 Imatinib PDGFR ABL, c-Kit II Feb 2001 Novartis
Advanced ≥10 Imatinib PDGFR ABL, c-Kit II Jun 2002 NCI
Refractory ≤21 Erlotinib EGFR I Feb 2004 COG/NCI
Refractory ≤21 Geﬁtinib EGFR I Sep 2005 St. Jude’s/Astra Zeneca
Metastatic/advanced/
recurrent
≥18 Sunitinib PDGFR c-KIT, VEGFR2,
FLT3 II Apr 2007 MSKCC/NCI
Advanced ≥13 Dasatinib SRC ABL, c-KIT,
EPHA2, PDGFR II May 2007 SARC/
Bristol-Myers Squibb
Metastatic/recurrent
≥1b u t
≤25 Dasatinib SRC ABL, c-KIT,
EPHA2, PDGFR I/II Sep 2008 Beckman Research Institute/
NCI
Metastatic/relapsed/
refractory
≥18 Pazopanib VEGFR1-3 PDGFR, c-KIT III Oct 2008 EORTC
Refractory/recurrent
≥2b u t
≤18 Cediranib VEGFR1-3 I Dec 2008 NCI
Monoclonalantibodies against RTK ligands
Metastatic
≥0.5 but
≤18 Bevacizumab VEGF N/A II Jul 2008 Hoﬀman-La Roche
Monoclonalantibodies against RTKs
Recurrent/refractory ≥2 R1507 IGF-1R N/A II Nov2007 Hoﬀmann-La Roche/SARC
Unresectable/locally
advanced/ metastatic
≥16 IMC-A12 IGF-1R N/A I/II Jun 2008 U. Chicago/NCI
Metastatic/advanced ≥12 IMC-A12 IGF-1R N/A II Jun 2008 ImClone LLC
Relapsed/refractory ≤30 Cixutumumab IGF-1R N/A II Jan 2009 COG/NCI
Metastatic ≤49 Cixutumumab IGF-1R N/A Pilot Jan 2010 COG/NCI
Obtained from clinicaltrials.gov website September 2010.
ErbB family proteins were found to be expressed in RMS
cells during screening for growth factor signaling pathway
members [51–53] .W h i l eE G F Ri sm o r eh i g h l ye x p r e s s e d
in eRMS tumor tissue [54–56] ErbB2 expression is more
prevalent in aRMS tumor tissue, and found in the majority
of RMS tumors in the head and neck [55, 57]. ErbB3
is also expressed in RMS cells and may play a role in
regulating diﬀerentiation, but ErbB4 has not been found
to be expressed in RMS cells [52]. Notably, to date no
mutations have been identiﬁed in the ErbB genes in RMS.
Blocking EGFR expression by antisense methods decreases
RMS cell proliferation in vitro [58]. Unfortunately, follow-
up preclinical testing of EGFR inhibitors in vivo has not
shown eﬃcacy. As an example, the small molecule inhibitor
lapatinib was tested in a PPTP screen but had little eﬀect in
solid tumors, suggesting that EGFR inhibition alone is not
suﬃcient to inhibit tumorigenesis.
Expression of an activating ErbB2 mutation in com-
bination with loss of p53 is suﬃcient to induce rhab-
domyosarcoma in mouse models. The resulting tumors
appear histologically similar to eRMS and express IGF-2
and IGF-1R [59]. This model was used to test a cancer
vaccine developed against the ErbB2 receptor, which was
successfulin preventingspontaneousRMS formationin50%
of mice examined [60]. Even though preclinical studies have
not shown promise as monotherapy, ErbB2 may play a
supportive role in RMS initiation.
Although inhibition of a single RTK may be beneﬁcial
in some circumstances, studies have suggested that this
approach will likely not be suﬃcient treatment for RMS, and
this appears to be true of EGFR. This has been appreciated
in preclinical models, and therefore human clinical trial
design has been modiﬁed to evaluate RTK inhibition in
combination with a cytotoxic agent. Geﬁtinib, a small
molecule inhibitor for EGFR, is being tested in phase I
clinical trials in pediatric solid tumors, in combination with
irinotecan [61]. Phase I clinical trials have been completed
for erlotinib, which also targets EGFR, done in combination
with temozolomide with few adverse eﬀects [62].
2.4. PDGFR. The PDGFR family of RTKs includes PDGFRα
and PDGFRβ, both 200kDa in size, which homo- or
heterodimerize to perform their signaling functions. While
PDGFRα is believed to be critical in the development ofSarcoma 5
neural, epithelial, and skeletal tissues, PDGFRβ is important
for blood vessel formation and hematopoiesis [63]. In
normal myogenesis, PDGFR activation is downregulated,
implying that loss of PDGFR signaling is involved in the
cell cycle exit that accompanies diﬀerentiation [64]. There
are four ligands for PDGFR, PDGF-A through PDGF-
D. In myoblasts, PDGF-B promotes cell migration and
proliferation and reduces diﬀerentiation in vitro [65, 66].
Therefore, PDGFR signaling is important for embryogene-
sis, and speciﬁcally myogenesis by regulating proliferation,
migration, and diﬀerentiation in myogenic precursors.
In RMS, the two PDGF receptors show increased expres-
sion [67–69], and PAX3-FOXO1 has been shown to activate
transcription of PDGFRα [70]. Imatinib, a small molecule
inhibitor of PDGFRs, has shown promise as an RMS therapy
inpreclinicalmodels.InamousegeneticmodelofRMS,high
expression of PDGFRα was observed in advanced tumors.
Loss of function of PDGFRα through siRNA or imatinib
induced tumor cell apoptosis. When imatinib or PDGFRα
blocking antibodies were used to treat RMS tumors in
these mice, 50% of mice had at least a partial reduction
of tumor growth [71]. PDGFR inhibition with sunitinib or
sorafenib showed promise in PPTP screening, promoting
tumor growth delay or inhibition, respectively (Table 1).
However, both sunitinib and sorafenib are known to inhibit
n u m e r o u so t h e rk i n a s e s ,s ot h e s ee ﬀects may not be due to
PDGFR inhibition alone. Although targeting PDGFR alone
has shown some promise in preclinical models, combina-
tion treatment with other chemotherapies may be more
beneﬁcial. In a mouse xenograft model of RMS, signiﬁcant
reduction of tumor burden was observed when imatinib
was used in combination with the topoisomerase inhibitor
topotecan [68].
In RMS patients, high expression of PDGFRs is asso-
ciated with decreases in failure-free and overall survival,
implicating PDGFR signaling in advanced stages of the
disease [53, 72]. The PDGFR inhibitor imatinib was tested
in advanced sarcomas of various types in a phase II trial.
Overall, the results did not support the use of imatinib as
a monotherapy, as only 2% of participants saw an eﬀect
resulting in partial or complete remission [73]. However,
combination treatment of imatinib with other targeted or
cytotoxic agents may be more beneﬁcial, as was seen in
preclinical models [68].
2.5. VEGFR. The VEGFR family of RTKs is comprised of
three members: VEGFR1 (FLT1), VEGFR2 (FLK1/KDR),
and VEGFR3 (FLT4). VEGFRs on endothelial cells regulate
multiple levels of angiogenesis by promoting endothelial
cell proliferation, migration, sprouting, and survival. These
receptors are activated by the ﬁve members of the VEGF
ligand family, VEGF-A through VEGF-D, and placental
growth factor (PlGF). VEGFs are produced in a wide variety
of tissues in response to hypoxia, in order to recruit vascu-
lature to the hypoxic area [74]. Interestingly, VEGFRs are
also expressed in myoblasts, and VEGF promotes myoblast
migration and survival. VEGFR expression is downregulated
upon myogenic diﬀerentiation, suggesting that prolonged
VEGFR signaling negatively regulates diﬀerentiation [75].
Similar to other cancer cells, when exposed to hypoxia,
RMS cells increase their secretion of VEGF [28]. RMS cells
express multiple isoforms of VEGF and VEGFRs, implying
that RMS tumors may utilize an autocrine loop to not only
promote tumor vascularity butinduce tumor growth as well.
This is supported by evidence that treatment of RMS cells in
culture promotes proliferation,while treatment with VEGFR
antibody blocked this eﬀect [76]. Furthermore, inhibition
of signaling downstream of VEGFR prevents expression
of VEGF by RMS cells, suggesting a feed-forward loop
promoting proliferation [77].
VEGFR inhibitors have shown promising results in
preclinical studies. Monoclonal antibodies to VEGF and
VEGFRsandsmall moleculeinhibitorstoVEGFRshavebeen
tested in mouse xenografts of RMS reduced tumor volume
and vascularity [50, 78–81]. Notably,cisplatin-resistant RMS
cells have increased expression of VEGF and VEGFRs,
implicating this autocrine signaling in RMS cell survival.
Cisplatin-resistant cells were sensitive to VEGFR inhibition,
which also blocked VEGF expression [82]. In this way,
highly aggressive tumor cells could be targeted with anti-
VEGFR therapy. In PPTP screening, VEGFR inhibitors have
also shown potential. The inhibitors AZD2171, sorafenib,
and sunitinib have each inhibited tumor growth in RMS
xenograft models. Currently, there are multiple clinical
trials testing VEGFR inhibition in RMS patients. These
include the small molecule inhibitors sunitinib, pazopanib,
and cediranib as well as the VEGF monoclonal antibody
bevacizumab. These studies are ongoing, but whether the
strong preclinical data for VEGFR inhibition will translate to
positive outcomes in clinical trials remains to be seen.
2.6. FGFR. The FGF receptor (FGFR) family consists of four
members, FGFR1 through 4, and vary insize (120–160kDa),
tissue distribution, and ligand aﬃnity. FGFRs aﬀect many
aspects of cell and organism physiology including prolifer-
ation, migration, and diﬀerentiation through activation by
FGF ligands, of which there are at least 23 [83]. FGFR4 is
considered to be the predominant FGFR in skeletal muscle,
regulatingskeletalmusclediﬀerentiationinchickmodelsand
muscle regeneration in mice [84, 85]. As is true for most
of the RTKs reviewed here, FGFR4 expression in myoblasts
decreases during diﬀerentiation, implying that FGFR4 is
important in myogenic precursors [86].
While FGFR1 and FGFR3 have been observed to have
increased expression in isolated RMS cases [87, 88], and
FGF ligands are expressed in RMS cells and tissues [51, 89],
signaling through FGFR4 has been the best characterized
in RMS tumorigenesis. FGFR4 expression is upregulated
in RMS cell lines and tumors [90, 91], and PAX3-FOXO1
promotes FGFR4 expression through 3  enhancer regions
[15]. Recently, FGFR4 was characterized as a regulator of
RMS tumor growth and metastasis. Activating mutations
within the kinase domain of FGFR4 were identiﬁed in
7% (7 of 94) of RMS cases, demonstrating overactive
FGFR4 signaling in RMS. These activating mutations were
suﬃcient to transform cells, increase RMS lung metastasis,
and decrease survival in mouse xenograft models. Blocking
FGFR4expression decreasedRMS tumorsize, cellmigration,6 Sarcoma
and metastasis, therefore characterizing FGFR4 as a possible
molecular target for RMS [92]. FGFR4 is the most recent
RTK implicated in RMS, and as such more research will be
needed to verify that FGFR4 is a rational therapeutic target
to pursue in preclinical and clinical settings.
3.RegulationofRTKExpressionin
Rhabdomyosarcoma
Since a signature mutation of aRMS is a chromosomal
translocation resulting in the PAX3/7-FOXO1 or PAX3-
NCOA1/2 transcription factors, much attention has been
focused on the genes regulated by these fusion proteins. In
fact, IGF-1R, MET, PDGFR, VEGFR1, and FGFR4 have all
beenshowntoberegulatedbyPAX3-FOXO1eitherbyactiva-
tionoftheRTKgenepromoterorthrough 5  or3  enhancing
elements [15, 39, 70, 93]. Since transcription factors are
generally diﬃcult to target due to chemical intractability,
druggablePAX3-FOXO1transcriptionaltargetssuchasRTKs
c o u l db em o r ep r o m i s i n gt h a ni n h i b i t i n gP A X 3 - F O X O 1
itself.
Another regulator of RTKs in RMS is the tumor sup-
pressor p53. The importance of p53 function in RMS has
been underscored by its role in promoting RMS in mouse
models when it is absent [46, 59]. Mutations in p53 have
been documented in both histological subtypes of RMS
[94], and IGF-1R and PDGFR have been deﬁnitively shown
to be upregulated in p53 loss-of-function experiments and
downregulated when nonmutated p53 is added back to these
systems [71,95].AlthoughPAX3-FOXO1and p53regulation
of RTK transcription in speciﬁc cases has been informative,
there is a need for a better understanding of when and how
RTK transcription is activated in RMS tumorigenesis.
Most recently, posttranscriptional regulation of genes
has been shown to play a role in RMS tumorigenesis. The
most focus has been on microRNAs mir-1 and mir-206, so-
called “myo-mirs.” Upon myogenic pathway induction, mir-
1 and mir-206 expression is upregulated, leading to post-
transcriptionaldownregulationofmir-1andmir-206targets.
Mir-1 and mir-206 have been found to be suﬃcienttoinduce
myogenic diﬀerentiation in myoblasts [96]. RMS cell lines
and tumors do not express mir-1 and mir-206 and therefore
are not able to posttranscriptionally regulate mir-1 and mir-
206 targets. Surprisingly, MET was found to be implicated
in the mir-206 pathway. MET contains two putative binding
sites for mir-206 in the MET 3  untranslated region. Ectopic
expression of mir-206 caused loss of MET expression,
induction of skeletal muscle diﬀerentiation markers, loss of
cell proliferation, and decreased tumor burden in mouse
RMS xenografts [97, 98]. The mechanism behind the loss of
mir-1 and mir-206 in RMS remains to be determined, but its
potential to downregulate therapeutic targets like MET may
hold promise for RMS treatments in the future.
4.TherapeuticPotentialforRTKInhibitionin
Rhabdomyosarcoma
As druggable receptors at the plasma membrane, RTKs have
been the focus of intense basic and pharmacologic research.
Small molecule inhibitors, ligand-neutralizing agents, and
monoclonal receptor-blocking antibodies have been gener-
ated for many of the RTKs expressed in RMS. However, it
is not likely that all of the RTKs in RMS will survive the
tests of robust preclinical testing and be evaluated in clinical
trials. Therefore, determining which target(s) are the most
promising andworthyofclinicaltrial assignment willbecrit-
ical. As described below, understanding their mechanisms of
upregulation, acquired resistance, and pathway crosstalk will
bekeytodetermining howtopharmacologically exploitRTK
signaling in RMS.
RTKs are only one of numerous and diverse signaling
pathways upregulated in cancer, so identifying the RTKs
upregulated in RMS is only a starting point to determine
theirpotentialastherapeutictargets.Inmany cases,blockade
of an upregulated RTK will cause cytostatic growth inhibi-
tion but not eliminate the cancer cells completely, leading
to emergence of resistant clones and refractory disease.
However, if the cells have become dependent on a particular
RTK signaling pathway for survival, so-called “oncogene
addiction” [99], blockade of these pathways should be more
eﬀective in disease eradication. The challenge then becomes
determining which RTKs confer oncogene addiction.
Another possibility is the presence of activating muta-
tions in RTKs. RTKs containing an activating mutation
are much more sensitive to inhibitors targeting that RTK
than cells or tumors with a wild-type RTK. An example
of this phenomenon was observed in non-small cell lung
carcinoma. In clinical trials of EGFR inhibitors, only 10%
of patients responded to treatment. Upon further investi-
gation, it was found that the responding patients harbored
somatic, activating EGFR mutations [100]. Similarly, in
PPTP screening, Kasumi-1 cells (which contain an activating
c-KIT mutation) were found to be particularly sensitive to
sorafenib [101]. To date, FGFR4 is the only RTK known to
have an activating mutation in RMS [92]. Deep sequencing
of RTKs implicated in RMS will need to be done to address
the possibility that other RTKs are mutated in RMS. A
second possibility is genomic ampliﬁcation or deletion or
sheer upregulation of RTKs or their signaling components.
This has already proven important in our understanding
of IGF-1R in RMS, as the loss of imprinting of the IGF-2
gene, orhigher expression levelsof IGF-1R,lead to oncogene
dependence even in the absence of an activating mutation
and confer sensitivity to RTK blockade [13, 16]. Similarly,
wild-type EGFR expression is upregulated in RMS cells.
AlthoughinhibitionofEGFRdoesnotappeartobeapromis-
ingcandidateformonotherapy,recentstudieshavesuggested
that EGFR could be used in targeted immunotherapy
applications [102]. In sum, understanding the underlying
genetic changes as well as utilizing upregulation of RTKs
through novel treatments will guide future RMS therapies.
A drawback of targeted therapies is the ability of tumor
cells to adapt and acquire resistance. Through further
upregulation of the therapeutic target, mutation of the
therapeutic target, or upregulation of a compensating RTK
or signaling pathway, cancer cells can rapidly adjust to
promote tumor cell survival [103]. For example, in the case
of IGF-1R blockade, RMS cells resistant to IGF-1R smallSarcoma 7
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Figure 2: RTKs associated with RMS and their known roles in RMS tumorigenesis or progression.
molecule inhibitors were found to have increased expression
ofEGFRwhen comparedto those cellsthatwere sensitive. To
this end, dual treatment with IGF-1R and EGFR inhibition
increased the antitumor eﬀect in RMS mouse xenograft
models [24]. Understanding how and if RMS cells adapt to
targeted therapies will be critical for successful treatment
options.
Although induction of resistance may pose a problem
for targeted therapy in RMS, crosstalk within signaling
pathways could provide a way to exploit RTK inhibition.
For example, the IGF-1R and VEGFR pathways exhibit
crosstalk in RMS, and by experimentally inhibiting IGF-
1R signaling, VEGF secretion is reduced [28]. Thus, IGF-
1R blockade has the potential to thwart both IGF-1R and
VEGFR pathways. In addition, many RTKs utilize redundant
downstream signaling components. Targeting more than
one RTK through multiple individual inhibitors, or using a
less speciﬁc inhibitor to block several RTKs simultaneously,
may prove beneﬁcial by strong inhibition of signaling at a
common node. Through a systematic and comprehensive
analysis of other as yet undescribed crosstalk mechanisms in
RMS, these dependencies can be identiﬁed and provide the
basis for further preclinical testing.
In addition to the theoretical attraction of combination
therapy on blocking signaling pathways, dual or multiple
inhibition of RTKs may oﬀer beneﬁcial eﬀects in inhibiting
the unique tumorigenic properties of cancer cells. The
“hallmarks of cancer” as deﬁned by Hanahan and Weinberg
[104], and further classiﬁed by Negrini et al. [105], represent
speciﬁctumorigenicpropertiesofthecancercell,asshownin
Figure 2. The RTKs we have described impact various cancer
cell characteristics. Through targeting of individual RTKs,
therapeutic intervention could inhibit distinct malignant
properties. When blocked in combination, inhibition of
multipleRTKscouldhaveaprofoundeﬀectontumorgrowth
and progression. Realistically, these positive outcomes on
tumor inhibition may be oﬀset by increased incidence
of toxicity and side eﬀects. Therefore, until both pre-
clinical and clinical studiesaddress these issues, combination
targetedtherapywillposeasizeablechallengeforresearchers.
5.PrioritizationofTherapeuticTargets
One of the most daunting challenges for pediatric oncology
clinical trial design is how to identify the strongest thera-
peutic candidates to pursue. Because of the limited number
of pediatric patients, only the most promising agents under
development as cancer treatment should be evaluated in a
clinical trial setting. As mentioned above, the PPTP provides
a preclinical platform to screen an experimental compound
against many types of pediatric cancers. To be considered
for a PPTP screen, there must be signiﬁcant rationale
for the proposed agent in pediatric cancers, including the
mechanism ofactionandinvitro andinvivoeﬃcacy.Insome
cases, evidence from pediatric preclinical models or adult
clinical trials is available, providing pharmacokinetic and
dosingdata.Thesecasesmayreceivepriority,astheyexpedite
some of the issues addressed in early clinical trials. In terms
ofprioritizationofRTKtargets,thereisaneed tounderstand
the genetic foundation behind activation of speciﬁc RTK
signaling pathways in RMS cells. Genetic screening of RTKs
for mutations or analysis of downstream signaling pathways
may provide insight into which therapeutic candidates could
have the most profound eﬀects on RMS cells. Clearly,
both large scale screens and mechanistic validation will be
necessary to prioritize the many candidates.8 Sarcoma
There are still numerous RTK targets that could be
utilized for RMS therapy and warrant further study to pro-
vide additional treatment opportunities. Additional study
of these targets in preclinical models will be necessary to
advance their use to clinical trials, either as single targeting
agents, multiple targeting agents, or single targeting agents
in combination with cytotoxic therapy. As we expand our
knowledge of how RTKs function individually or together,
the potential for utilizing RTK inhibition could be a turning
point in a new era of targeted therapy for RMS. The future
of RMS therapies holds promise and will provide improved
options for RMS patients, including those in high risk
groups.
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